U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H16N2.ClH
Molecular Weight 224.73
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENPROPOREX HYDROCHLORIDE

SMILES

Cl.CC(CC1=CC=CC=C1)NCCC#N

InChI

InChIKey=ZBRZSJUFJUMKIM-UHFFFAOYSA-N
InChI=1S/C12H16N2.ClH/c1-11(14-9-5-8-13)10-12-6-3-2-4-7-12;/h2-4,6-7,11,14H,5,9-10H2,1H3;1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C12H16N2
Molecular Weight 188.2688
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: http://en.pharmacodia.com/web/drug/1_10952.html | http://www.ndrugs.com/?s=fenproporex%20hydrochloride&t=dosage | http://www.doctoralia.com.mx/medicamento/esbelcaps-53723

Fenproporex is a central and indirect-acting sympathomimetic. It was developed as an anorectic drug. Their anorectic effects are believed to be a result of adrenergic activation. Fenproporex has never been approved by the US Food and Drug Administration (FDA) for sale in the US due to lack of efficacy and safety data. There is a paucity of randomized, placebo-controlled trials on Fenproporex. These studies suggest that Fenproporex is modestly effective in promoting weight loss. Data from these studies are insufficient to determine the risk-benefit profile of Fenproporex. Abuse potential and amphetamine-like adverse effects are causes for concern. Adverse effect most frequently reported are: insomnia, anxiety, depression, irritability, dry mouth.

CNS Activity

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Substrate
661
Cytochrome P450 2B6
19
Target ID: P20813
Gene ID: 1555.0
Gene Symbol: CYP2B6
Target Organism: Homo sapiens (Human)
Substrate
661
Substrate
661
Substrate
661
Activator
1430
Sodium-Potassium-Exchanging ATPase (Rat)
3
Target ID: Sodium-Potassium-Exchanging ATPase (Rat)
Modulator
828
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Withdrawn
Esbelcaps

Approved Use

Anorexigenic. Assist in the treatment of obesity. An adjuvant to the establishment of a low-calorie diet.
PubMed

PubMed

TitleDatePubMed
Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives.
2002 Apr
Treatment of obesity: an update on anti-obesity medications.
2003 Feb
Fenproporex N-dealkylation to amphetamine--enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats.
2004 Sep 1
Abusive prescription of psychostimulants: a study of two cases.
2006 Mar
Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment.
2010 Aug 18
Long-term pharmacotherapy for obesity in elderly patients: a retrospective evaluation of medical records from a specialized obesity outpatient clinic.
2010 Jun 1
Dependence on the Brazilian diet pill: a case report.
2010 May-Jun
Patents

Patents

JP2011529923A
42
US3485924
3

Sample Use Guides

In Vivo Use Guide
The initial dose is 10 mg/day. The dose might be increased up to 15 mg/day.
Route of Administration: Oral
In Vitro Use Guide
In presence of 3 uM inhibitor quinidine and 50 uM Fenproporex the metabolite formation of the S(+)-enantiomer was significantly (P value 0.0145) inhibited.
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:30:14 UTC 2023
Edited
by admin
on Fri Dec 15 18:30:14 UTC 2023
Record UNII
09PE91J6V6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FENPROPOREX HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
Fenproporex hydrochloride [WHO-DD]
Common Name English
SOLVOLIP
Brand Name English
FENPROPOREX HCL
Common Name English
GACILIN
Brand Name English
(±)-3-(.ALPHA.-METHYLPHENETHYLAMINO)PROPIONITRILE HYDROCHLORIDE
Systematic Name English
(±)-N-2-CYANOETHYLAMPHETAMINE HYDROCHLORIDE
Systematic Name English
FENPROPOREX HYDROCHLORIDE [MI]
Common Name English
N-2-CYANOETHYLAMPHETAMINE HYDROCHLORIDE
Systematic Name English
FENPROPOREX HYDROCHLORIDE [MART.]
Common Name English
Code System Code Type Description
FDA UNII
09PE91J6V6
Created by admin on Fri Dec 15 18:30:15 UTC 2023 , Edited by admin on Fri Dec 15 18:30:15 UTC 2023
PRIMARY
CAS
16359-54-9
Created by admin on Fri Dec 15 18:30:14 UTC 2023 , Edited by admin on Fri Dec 15 18:30:14 UTC 2023
PRIMARY
EVMPD
SUB02126MIG
Created by admin on Fri Dec 15 18:30:15 UTC 2023 , Edited by admin on Fri Dec 15 18:30:15 UTC 2023
PRIMARY
SMS_ID
100000086985
Created by admin on Fri Dec 15 18:30:15 UTC 2023 , Edited by admin on Fri Dec 15 18:30:15 UTC 2023
PRIMARY
EPA CompTox
DTXSID10936846
Created by admin on Fri Dec 15 18:30:15 UTC 2023 , Edited by admin on Fri Dec 15 18:30:15 UTC 2023
PRIMARY
MERCK INDEX
m5292
Created by admin on Fri Dec 15 18:30:15 UTC 2023 , Edited by admin on Fri Dec 15 18:30:15 UTC 2023
PRIMARY Merck Index
RXCUI
236528
Created by admin on Fri Dec 15 18:30:15 UTC 2023 , Edited by admin on Fri Dec 15 18:30:15 UTC 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
240-420-3
Created by admin on Fri Dec 15 18:30:15 UTC 2023 , Edited by admin on Fri Dec 15 18:30:15 UTC 2023
PRIMARY
PUBCHEM
161245
Created by admin on Fri Dec 15 18:30:15 UTC 2023 , Edited by admin on Fri Dec 15 18:30:15 UTC 2023
PRIMARY
CAS
18305-29-8
Created by admin on Fri Dec 15 18:30:14 UTC 2023 , Edited by admin on Fri Dec 15 18:30:14 UTC 2023
SUPERSEDED
Related Record Type Details
Structure of FENPROPOREX
PARENT -> SALT/SOLVATE
Structure of FENPROPOREX HYDROCHLORIDE, (+)-
ENANTIOMER -> RACEMATE
Structure of FENPROPOREX HYDROCHLORIDE, (-)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of FENPROPOREX
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966